STING agonist-22 (CF501) is a potent non-nucleotide STING agonist. STING agonist-22 is a adjuvant by activating STING to induce the type I interferon (IFN-I) response and proinflammatory cytokine production. STING agonist-22 can be used as an adjuvant to boost the original protein vaccine, producing potent, broad, and long-term immune protection. STING agonist-22 can be used for SARS-CoV-2 variants and sarbecovirus diseases research. In Vitro STING agonist-22 (CF501) leads to rapid and robust activation of innate immune responses in THP-1 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo STING agonist-22 (CF501) robustly, but transiently, activates innate immunity with acceptable safety profile in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Balb/c mice (female, six weeks old) Dosage: 20, 75 μg Administration: Intramuscular injection Result: Although innate immunity was activated only transiently by CF501, it should be sufficient to stimulate the required humoral and cellular immune responses. The half-life of CF501 was 0.5 h and there was no detectable CF501 in the plasma after 2 h of the injection. Form:Solid